The Cystinosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cystinosis: An Overview
Cystinosis is a rare genetic, metabolic, lysosomal storage disease caused by mutations in the CTNS gene on chromosome 17p13. So far, over 100 pathogenic mutations have been reported in the literature. The condition results in an abnormal accumulation of the amino acid cystine in various organs and tissues of the body, such as the kidneys, eyes, muscles, pancreas, and brain.
Cystinosis Market Key Facts
The total prevalent population of Cystinosis in seven major markets was 2,956 in 2017.
Among the European countries, the United Kingdom had the highest prevalent population of Cystinosis with 554 cases and Italy had the lowest prevalent population with 105 cases in 2017.
In 2017, there was a total of 630 diagnosed prevalent cases of Cystinosis in the United States.
Out of the total diagnosed prevalent cases of cystinosis in Japan, 22 cases accounted for infantile nephropathic cystinosis, 1 case accounted for Juvenile nephropathic cystinosis and 1 case accounted for Adult-onset (Ocular, or non-nephropathic cystinosis) in 2017.
The market size of Cystinosis in seven major markets (7MM) is estimated to be USD 130.46 million in 2017. As per DelveInsight, the United States accounts for the highest market size of Cystinosis, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan. Among the EU5 countries, the UK had the highest market size in 2017, while Italy had the lowest market size of Cystinosis.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Cystinosis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Cystinosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- Cystinosis Therapeutics Market
The epidemiology section covers insights about the historical and current Cystinosis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Cystinosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cystinosis market or expected to get launched in the market during the study period. The analysis covers Cystinosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Cystinosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
As per Delveinsight, owing to the launch of upcoming therapies, the Cystinosis market size shall increase during the forecast period.
Some of the key Companies in the Cystinosis Market Includes:
And many others.
Cystinosis Therapies covered in the report include:
Procysbi (cysteamine bitartrate)
Cystadrops (cysteamine hydrochloride)
Cystaran (cysteamine hydrochloride)
Cystagon (cysteamine bitartrate)
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- Chronic Insomnia Therapeutics Landscape
Table of Content
1. Key Insights
2. Executive Summary
3. Cystinosis Competitive Intelligence Analysis
4. Cystinosis Market Overview at a Glance
5. Cystinosis Disease Background and Overview
6. Cystinosis Patient Journey
7. Cystinosis Epidemiology and Patient Population
8. Cystinosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Cystinosis Unmet Needs
10. Key Endpoints of Cystinosis Treatment
11. Cystinosis Marketed Products
12. Cystinosis Emerging Therapies
13. Cystinosis Seven Major Market Analysis
14. Attribute Analysis
15. Cystinosis Market Outlook (7 major markets)
16. Cystinosis Access and Reimbursement Overview
17. KOL Views on the Cystinosis Market.
18. Cystinosis Market Drivers
19. Cystinosis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/cystinosis-market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States